Acerus Logo.jpg
Acerus Announces Participation in HC Wainwright Conference
August 23, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today announced that it will participate in the H.C. Wainwright 23rd...
Acerus Logo.jpg
Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
August 12, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today announced that it had accepted a Part 36 settlement offer made...
Acerus Logo.jpg
Acerus Reports Fiscal 2021 Second Quarter Financial Results
August 10, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month...
Acerus Logo.jpg
Acerus to Report Q2-2021 Financial Results and Host Investor Call
August 03, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2021 financial and operating results on Tuesday, August 10, 2021...
Acerus Logo.jpg
Acerus Provides Update on Litigation with Recipharm
July 12, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary...
Acerus Logo.jpg
Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States
June 29, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, June 29, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription...
Acerus Logo.jpg
Acerus Announces Voting Results for the 2021 Annual Meeting
June 14, 2021 17:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on...
Acerus Logo.jpg
Acerus Reports First Quarter 2021 Financial Results
May 13, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period...
Acerus Logo.jpg
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
May 10, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, May 10, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription...
Acerus Logo.jpg
Acerus to Report Q1-2021 Financial Results and Host Investor Call
May 06, 2021 07:30 ET | Acerus Pharmaceuticals Corporation
TORONTO, May 06, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2021 financial and operating results on Thursday, May 13, 2021...